Overview

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Status:
Terminated
Trial end date:
2018-12-18
Target enrollment:
Participant gender:
Summary
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO is superior to IVT anti-VEGF agent used alone.
Phase:
Phase 3
Details
Lead Sponsor:
Clearside Biomedical, Inc.
Treatments:
Bevacizumab
Ranibizumab
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide